From left: Cara CEO Derek Chalmers and board member Christopher Posner
Weeks into first approval, Cara waves goodbye to founding CEO in favor of board member
A biotech’s first drug approval is a process often years in the making and a crowning achievement for founder-CEOs who have run the race from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
